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Abstract: Baricitinib is an innovative small-molecule drug that reversibly inhibits continuous 
activation of JAK/STAT pathway, thus reducing joint inflammation. The drug was approved 
for use as monotherapy or in combination with methotrexate (MTX) in the treatment of adults 
with moderately to severely active rheumatoid arthritis (RA). The aim of this paper was to 
review the studies on pharmacology, mode of action, pharmacokinetics, efficacy, and safety 
of baricitinib in patients with RA. Baricitinib provides an innovative approach to modulating 
the immune and inflammatory response in patients with RA, which is especially important in 
individuals who do not respond to disease-modifying antirheumatic drugs or standard biologic 
drugs (tumor necrosis factor inhibitors) or who lose response over time. Baricitinib therapy 
reduces symptoms of RA and improves the quality of life. Moreover, it has shown high efficacy 
and an acceptable safety profile in Phase III randomized controlled trials (RCTs) and become 
another JAK inhibitor approved for RA treatment, providing a useful alternative option. RCTs 
have revealed a significant benefit of baricitinib over placebo, MTX, and adalimumab in terms 
of standard efficacy outcomes, especially the American College of Rheumatology ACR20, 
ACR50, and ACR70 response rates. Additionally, a clinically meaningful improvement in 
patient-reported outcomes, including the quality of life, compared with placebo has been reported. 
The safety profile seems acceptable, although some rare but potentially severe adverse events 
have been observed, such as serious infections, opportunistic infections (eg, herpes zoster), 
malignancies, and cardiac or hepatic disorders. Baricitinib administered at an approved dose 
of 2 or 4 mg once daily offers a novel and promising alternative to parenterally administered 
biologic drugs used in RA treatment.
Keywords: JAK inhibitor, baricitinib, efficacy, rheumatoid arthritis, safety
Introduction
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by 
persistent joint inflammation leading to loss of joint function as well as cartilage and 
bone damage. Chronic, progressive course of the disease results in disability, reduced 
quality of life, as well as higher comorbidity and mortality rates.1,2 With an estimated 
prevalence of 0.3%–1%, RA is the most common inflammatory joint disease in adults.3,4
The aim of RA treatment is to achieve remission or reduction of disease activity by 
preventing inflammation, progression of joint damage, and disability.3,5 RA treatment 
has been significantly improved over the past several decades, with numerous effective 
targeted drugs currently available.5 The treatment options include NSAIDs, glucocor-
ticoids, conventional synthetic disease-modifying antirheumatic drugs (csDMARDs; 
such as methotrexate [MTX], sulfasalazine, and leflunomide), biologic DMARDs 
(bDMARDs; including tumor necrosis factor [TNF] inhibitors such as adalimumab, 
infliximab, certolizumab pegol, golimumab, and etanercept, as well as non-TNF drugs 
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such as abatacept, rituximab, and tocilizumab), biosimilar 
DMARDs, and targeted synthetic DMARDs (tofacitinib, 
baricitinib).3–5
Therapy with DMARDs should be started immediately 
after the diagnosis of RA and should be adjusted to disease 
activity and individual prognostic factors.3,5 According to 
the latest clinical guidelines,3–5 MTX monotherapy is recom-
mended as a first-line treatment, with concomitant short-term 
low-dose glucocorticoid therapy where indicated. In patients 
who fail this treatment due to an inadequate response to or intol-
erance of MTX, another synthetic DMARD (sulfasalazine or 
leflunomide), or a combination of a synthetic DMARD (MTX) 
with a bDMARD or targeted synthetic DMARD (tofacitinib, 
baricitinib) should be considered depending on the patient’s 
condition. Patients with poor response to the first bDMARD 
or targeted synthetic DMARD should be offered another 
bDMARD or targeted DMARD. Patients who fail treatment 
with the first TNF inhibitor can be given either a second TNF 
inhibitor or a bDMARD with a different mode of action.3–5
The standard end point to measure the efficacy of 
treatment in clinical trials on RA is the American Col-
lege of Rheumatology (ACR) response rate. The ACR20, 
ACR50, and ACR70 response is defined as a reduction 
of $20%, $50%, and $70%, respectively, in the number of 
tender and swollen joints and in at least three of the following 
ACR core measures: patient’s assessment of pain, physician’s 
global assessment of disease, patient’s global assessment of 
disease, physical function as assessed by the Health Assess-
ment Questionnaire-Disability Index (HAQ-DI), and the level 
of acute-phase reactants: erythrocyte sedimentation rate or 
C-reactive protein.6
The aim of this paper was to review the mode of action, 
pharmacology, pharmacokinetics, as well as the efficacy 
and safety of a targeted synthetic DMARD, baricitinib, as 
monotherapy or in combination with csDMARDs, in patients 
with RA. A literature search was conducted by two review-
ers in the main electronic databases: Medline via PubMed, 
EMBASE, and Cochrane Central Register of Controlled 
Trials (last search September 2018). The keywords 
“baricitinib” and “rheumatoid arthritis” were used for the 
search. The appropriate randomized controlled trials (RCTs) 
and their long-term extensions (LTEs) published in English 
were selected based on the titles and abstracts. An additional 
analysis of the safety profile, especially regarding adverse 
events (AEs) of special interest, was performed according 
to pooled data from the main clinical trials and Summary of 
Product Characteristics. Moreover, the ClinicalTrials.gov 
website was searched to find ongoing clinical trials assess-
ing the efficacy of baricitinib in conditions other than RA.
Baricitinib: mechanism of action 
and pharmacology
Baricitinib is a synthetic small-molecule drug, which modu-
lates cytokine signaling by targeting the JAK/STAT pathway 
involved in inflammatory response.7 This oral drug is a pref-
erential and highly selective JAK1 and JAK2 inhibitor that 
has shown efficacy in Phase II studies in patients with RA 
who had an inadequate response to csDMARDs.8,9 The JAK 
family, consisting of JAK1, JAK2, and tyrosine kinase 2, is 
involved in the signaling pathways of various cytokines and 
growth factors that have been implicated in the pathogenesis 
of RA.10 Activation of proinflammatory cytokine pathways 
is essential in the disease pathogenesis, especially of IL-6, 
IL-2, and interferons, which use JAK-dependent pathways.11
Baricitinib preferentially targets signaling receptors 
associated with JAK1 and JAK2 pathways believed to be 
important in the pathogenesis of RA. This results in the inhi-
bition of transmigration of STAT molecules to the nucleus. 
JAK1 and JAK2 are widely expressed and mediate signal-
ing of multiple cytokines implicated in the pathogenesis of 
RA, such as interferons, IL-6, and granulocyte macrophage 
colony-stimulating factor.12 Baricitinib has a short half-life. 
The pharmacokinetic profile of the molecule is characterized 
by rapid absorption and elimination in humans, with a time 
to peak concentration of approximately 1.5 hours following 
oral administration and a half-life of approximately 3 hours. 
In humans, approximately 75% of the administered dose is 
cleared in the urine, while about 20%, in the feces; the drug 
metabolism is mediated by CYP3A4, with ,10% of the dose 
identified as undergoing biotransformation.13
The European Commission granted a marketing authori-
zation valid throughout the European Union for Olumiant® 
(Eli Lilly) on 13 February 2017. It was approved for use at 
a dose of 2 or 4 mg administered orally, in combination with 
MTX, for the treatment of moderately to severely active RA 
in adult patients. In case of intolerance or contraindications to 
MTX, it can be given as monotherapy.13 In May 2018, the US 
Food and Drug Administration approved the 2 mg once-daily 
dose of Olumiant® for the treatment of adults with moderately 
to severely active RA who have had an inadequate response 
to one or more therapies with a TNF inhibitor.14
Clinical efficacy of baricitinib
Four large Phase III trials assessing the efficacy and safety 
of baricitinib at a registered dose of 2 or 4 mg once daily in 
patients with RA were identified: RA-BEACON,15–17 RA-
BUILD,18,19 RA-BEAM,20,21 and RA-BEGIN22,23 (Table 1). 
In the randomized double-blind RA-BEACON trial,15–17 
527 patients with moderate-to-severe RA were assigned in 
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The efficacy and safety of baricitinib administered at a 
dose from 1 to 8 mg once daily were assessed in randomized 
multicenter Phase IIb double-blind trials in patients with 
moderately to severely active RA.8,9,11,24,25 In the studies by 
Keystone et al8 and Tanaka et al,9 conducted in patients with 
inadequate response to MTX therapy, significantly more 
number of patients who received baricitinib at a dose of 
4 mg once daily achieved the ACR20 and ACR50 response 
after 12 weeks than patients receiving placebo (Table 1). 
Moreover, the trial by Keystone et al8 showed that the 2 mg 
dose of baricitinib was less effective in terms of the ACR20, 
ACR50, and ACR70 response rates as well as low disease 
activity or remission at 12 and 24 weeks than the 4 mg dose. 
According to the results, the 4 mg dose of baricitinib was 
considered optimal for assessment in Phase III trials, while 
the 2 mg dose proved less effective.8
In the trial by Tanaka et al,9 baricitinib (4 mg) therapy 
resulted in a significant improvement of each ACR com-
ponent, as compared with placebo (Table 1). In the group 
receiving baricitinib at a dose of 2 mg, the percentage of 
patients with the ACR20 response was significantly higher 
than in the group receiving placebo. However, the response 
to treatment did not occur as quickly as with the higher doses. 
The benefits of treatment with the 4 mg dose were observed 
immediately after 2 weeks, while the most notable effects 
were reported at 8 weeks.9 The percentage of patients who 
achieved the ACR20 response was higher at 12 weeks in all 
groups treated with baricitinib as compared with the placebo 
group. The percentage of patients who achieved ACR50 
or ACR70 response also increased during the 12 weeks of 
therapy.9 Extended-phase studies24,25 revealed that the per-
centage of patients with ACR20 and ACR50 response was 
maintained or increased in the long-term follow-up.
Effect of baricitinib on patient-
related outcomes (PROs)
Refractory patients with a previously inadequate response 
to bDMARDs who were treated with baricitinib (2 and 
4 mg) showed a significant improvement over placebo 
in most PROs evaluated in the RA-BEACON trial.17 
Improvements were generally faster and more notable in 
patients receiving baricitinib at a dose of 4 mg than those 
receiving 2 mg dose and were maintained until week 24. 
Compared with placebo-treated patients, a higher number 
of those receiving baricitinib reported improvements in 
the patient’s global assessment of disease activity (PtGA; 
P#0.001) and pain (P#0.001), a reduction in the duration 
of morning joint stiffness (P,0.01) and fatigue (Functional 
Assessment of Chronic Illness Therapy-Fatigue [FACIT-F] 
a 1:1:1 ratio to baricitinib at a dose of 2 mg, baricitinib at a 
dose of 4 mg, or placebo. Before the study, patients showed 
an inadequate response or intolerance to at least one therapy 
with TNF inhibitors. Patients who received baricitinib had 
significantly higher ACR20 and ACR50 response rates 
than patients given placebo. At 12 weeks, the percentage of 
patients who achieved the ACR20 response was significantly 
higher in the group treated with baricitinib (2 and 4 mg) than 
in the placebo group (49% and 55% vs 27%). Similarly, 
more patients in the 2 and 4 mg baricitinib groups achieved 
the ACR50 response at 12 weeks than in the placebo group 
(20%, 28%, and 8%, respectively). A significant benefit of 
baricitinib over placebo in terms of ACR20 and ACR50 
response rates was also maintained at 24 weeks of therapy.
In the RA-BUILD trial,18,19 684 patients with active RA 
and an inadequate response to one or more csDMARDs 
were randomized into three groups: placebo, baricitinib at 
a dose of 2 mg, or baricitinib at a dose of 4 mg once daily 
over 12 weeks. The ACR20 response was achieved by a 
higher percentage of patients in baricitinib groups than in 
the placebo group (66% in the 2 mg dose group, 62% in the 
4 mg dose group, and 39% in the placebo group; P#0.001).
The efficacy of baricitinib was confirmed in the RA-
BEAM20,21 trial, which included 1,305 patients with active 
RA and an inadequate response to MTX. The trial compared 
baricitinib at a dose of 4 mg with adalimumab and placebo. 
Baricitinib was shown to decrease the activity of the disease 
at 12 and 24 weeks. At 12 weeks, the ACR20 response was 
achieved by 70% of patients receiving baricitinib and 40% of 
those receiving placebo (P,0.001). A significant improvement 
was also observed in the case of baricitinib administration com-
pared with adalimumab: the ACR20 response was achieved 
by 70% in baricitinib group and 61% in adalimumab group 
(P=0.014). The effect was maintained at 24 weeks of therapy. 
As for the other secondary and exploratory end points, the 
comparison showed a benefit of baricitinib over placebo in the 
ACR50 response rate at 12 weeks (45% vs 17%; P#0.001) and 
at 24 weeks (51% vs 19%; P#0.001), as well as of baricitinib 
over adalimumab at 12 weeks (45% vs 35%; P#0.01).
The RA-BEGIN trial22,23 was a randomized double-blind 
trial with an active comparator. Patients were randomized 
in a 4:3:4 ratio to receive MTX monotherapy (given orally 
once a week), baricitinib (4 mg once daily), or a combina-
tion of baricitinib 4 mg and MTX (baricitinib plus MTX). 
Baricitinib decreased the activity of RA in patients without 
prior DMARD therapy or with prior limited MTX therapy. 
Monotherapy with baricitinib was shown to outweigh mono-
therapy with MTX at 24 weeks, with the ACR20 response 
rate being 77% and 62%, respectively (P#0.01).
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score $3.56; P#0.05), and normal physical functioning 
(HAQ-DI score ,0.5; P#0.001). No significant differences 
were observed between patients treated with baricitinib and 
placebo in the 36-item Short Form Health Survey (SF-36) 
mental component score (MCS) and physical component 
score (PCS), which is consistent with observations from 
previous clinical trials.17
Compared with placebo, baricitinib at a dose of 2 or 4 mg 
resulted in a significant improvement in PROs across dif-
ferent domains of RA, including physical function, fatigue, 
pain, and quality of life. The 4 mg dose was associated with 
a more rapid improvement compared with the 2 mg dose. 
Significant improvements were observed for both baricitinib 
groups (2 and 4 mg) vs placebo in health-related quality of 
life (HRQoL), as measured by the EuroQoL-5D (EQ-5D) 
and SF-36 PCS at week 12. Patients in the baricitinib 
groups reported a significantly greater improvement in the 
FACIT-F score and EQ visual analog scale, PtGA, daily 
diary measures, and HAQ-DI at week 24, as compared with 
the placebo group.19
The above findings were confirmed by other studies.19,23 
Baricitinib treatment resulted in a significantly greater 
improvement compared with placebo or adalimumab treat-
ment in most of the prespecified PROs, including physical 
function, pain, fatigue, duration and severity of morning 
joint stiffness, as well as HRQoL (SF-36 PCS, EQ-5D index 
scores, and Activity Impairment Questionnaire: Rheumatoid 
Arthritis [WPAI-RA] daily activity) at 12 weeks. A signifi-
cant improvement in the worst tiredness and worst joint pain 
was observed for baricitinib vs placebo and adalimumab at 
12 weeks (P#0.05). Furthermore, compared with placebo 
and adalimumab, baricitinib resulted in a rapid improvement 
in the diary PROs, including morning joint stiffness duration 
and severity, with significant differences vs placebo observed 
within a few days from treatment initiation. Compared with 
adalimumab, improvements in physical function, pain, 
fatigue, and HRQoL (eg, SF-36 PCS and EQ-5D) were 
maintained until week 52.21
In the RA-BEGIN23 study, patients in both baricitinib 
groups (baricitinib monotherapy and baricitinib plus MTX), 
compared with MTX-treated patients, reported a greater 
improvement (P#0.01) in HAQ-DI, PtGA, pain, fatigue, 
worst join pain, SF-36 PCS, and EQ-5D at 24 and 52 weeks. 
They also reported a significant improvement (P#0.01) in 
the SF-36 MCS at 52 weeks. In addition, they showed an 
improvement (P#0.05) in the WPAI-RA score at 24 weeks. 
At week 52, significant improvement in WPAI-RA daily 
activity and work productivity scores was maintained only 
in the baricitinib-plus-MTX group compared with the MTX 
group.23
Summarizing, patients with active RA treated with 
baricitinib reported sustained, clinically meaningful, and 
significant improvements in most PROs compared to those 
treated with placebo, MTX, and adalimumab.17,19,21,23
Safety and tolerability of baricitinib
The safety and tolerability of baricitinib in patients 
with a moderate-to-severe RA were studied in several 
RCTs8,9,15,18,20,22 as well as an integrated analysis of nine 
trials, which evaluated baricitinib at doses ranging from 
1 to 15 mg daily, with a maximum drug exposure period of 
up to 5.5 years.26,27 The general safety profile of baricitinib 
administered at an approved dose of 2 or 4 mg once daily 
was found to be acceptable irrespective of the concomitant 
use of csDMARDs.
In the studies by Tanaka et al9 and Keystone et al,8 with a 
relatively small population of patients (,60 in groups receiv-
ing baricitinib) and a short initial follow-up of 12 weeks, the 
incidence of treatment-emergent AEs did not differ between 
patients receiving 2 mg baricitinib (46%–50%), those receiv-
ing 4 mg baricitinib (42%–54%), and the placebo group 
(46%–53%). A similar tendency was observed in the large 
RA-BUILD study (with >200 patients in each group),18 with 
a comparable rate of AEs after 24 weeks of exposure between 
2 mg baricitinib, 4 mg baricitinib, and placebo groups (67%, 
71%, and 71%, respectively). In the other studies with a 
follow-up of 24 weeks, RA-BEACON15 and RA-BEAM,20 the 
percentage of patients who experienced any AEs was higher 
in the 2 and 4 mg baricitinib groups (71% and 71%–77%, 
respectively) than in the placebo group (60%–64%). As 
compared with an active comparator, the incidence of AEs 
at 52 weeks was similar with 4 mg baricitinib and adalim-
umab (79% vs 77%)20 as well as with 4 mg baricitinib and 
MTX (71% vs 72%);22 coadministration of MTX with 4 mg 
baricitinib increased the risk of AEs to 78%.22
The studies by Tanaka et al9 and Keystone et al8 revealed 
a similar, generally low incidence of serious AEs (SAEs) 
in a short-term follow-up of 12 weeks: 2%–3% in placebo 
group, 4%–6% in 2 mg baricitinib group, and interestingly, 
0% in 4 mg baricitinib group. A similar incidence rate was 
observed in the RA-BUILD trial after 24 weeks of treatment: 
5%, 3%, and 5% in the placebo, 2 mg baricitinib, and 4 mg 
baricitinib groups, respectively.18 A slightly higher rate of 
SAEs at 24 weeks was reported in the RA-BEACON study: 
7%, 4%, and 10% in the placebo, 2 mg baricitinib, and 
4 mg baricitinib groups, respectively.15 As compared with 
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adalimumab (2%), the overall incidence of SAEs was higher 
after administration of baricitinib at a dose of 4 mg (5%) or 
placebo (5%); however, no particular type of event was noted 
at a lower rate in the adalimumab group at 24 weeks in the 
RA-BEAM study.20 The rates of SAEs were similar for MTX 
monotherapy (10%), monotherapy with 4 mg baricitinib 
(8%), and combined treatment with 4 mg baricitinib and 
MTX (8%) at 52 weeks in the RA-BEGIN study.22
The rates of treatment discontinuation due to AEs were 
generally low in baricitinib groups,8,9,15,18,20,22 irrespective of 
the concomitant use of MTX or other conventional DMARDs, 
and did not exceed 11%.22 In the study by Tanaka et al,9 dur-
ing the 12-week follow-up, none of the patients in the 2 and 
4 mg baricitinib groups stopped treatment due to AEs, as 
compared with 2% in the placebo group. In the 24-week 
follow-up, discontinuation due to AEs was reported for 3%20 
to 4%15,18 in placebo, 2%8 to 4%15,18 in 2 mg baricitinib, 4%8 
to 6%15 in 4 mg baricitinib, and 2%20 in adalimumab groups. 
In the RA-BEGIN trial,22 treatment discontinuation due to 
AEs at 52 weeks was reported for 11% of patients who 
received baricitinib with MTX, compared with 5% of those 
receiving MTX monotherapy and 6% of those on baricitinib 
alone. The integrated analysis of eight RCTs and one LTE 
study, including 3,492 patients treated with baricitinib for 
a total of 6,637 patient-years (PYs) and with a maximum 
drug exposure period of 5.5 years, revealed a similar risk 
of treatment discontinuation due to AEs in 4 mg baricitinib 
and placebo groups.26,27 The incidence rate (IR) of death dur-
ing baricitinib treatment at a dose of 4 mg was estimated at 
0.7 (95% CI: 0.1; 2.1) for 100 PYs and was higher as com-
pared with that calculated for baricitinib groups, regardless 
of the dose (IR =0.33 [95% CI: 0.2; 0.5]), but similar to that 
for placebo (IR =0.5 [95% CI: 0.1; 1.8]).26,27
The safety profile of baricitinib may slightly differ 
depending on the patients’ age. A post hoc analysis of 
two Phase III studies evaluating the use of 4 mg barici-
tinib in patients with inadequate response to a csDMARD 
revealed that the risk of AEs increased with the patients’ 
age.28 A numerically higher percentage of patients in the 
older age group ($65 years) reported AEs (99.3%), SAEs 
(8.8%), and serious infections (2.9%) than in the younger 
age groups (,50 years: AEs – 88.4%, SAEs – 3.1%, 
serious infections – 1.2%; $50 to ,65 years: AEs – 
92.8%, SAEs – 4.7%, serious infections – 0.6%). It should 
be noted that the incidence of AEs, SAEs, or withdrawals due 
to AEs in baricitinib-treated patients was generally similar to 
that observed for age-matched placebo-treated patients (for 
placebo group ,50 years: AEs – 83.5%, SAEs – 3.9%; $50 
to ,65 years: AEs – 93.4%, SAEs – 3.2%; $65 years: 
AEs – 98.2%, SAEs – 10.6%). This may result from a higher 
incidence of comorbidities and changes in pharmacodynamics 
in older patients, so elderly people with RA should be 
followed very carefully during baricitinib therapy.28
AEs of special interest
Patients with RA have a higher incidence of comorbidities 
such as infections, cardiovascular events, or some types 
of cancer, as compared with the healthy population.29,30 
Considering the disease background as well as the type 
and spectrum of applied treatment, it may be difficult to 
establish whether the comorbidities are the result only of 
RA or administered therapies.29 However, close monitoring 
of patients and screening for the above events is necessary 
irrespective of their origin.
As expected, the most common AEs reported during 
baricitinib therapy were infections, including bronchitis,15,20 
upper respiratory tract infections,15,18,20,22 nasopharyngi-
tis,9,15,20 pharyngitis,9,15,20 sinusitis,15 and urinary tract infec-
tions.15.20.22 The rates of serious infections were comparable 
between groups treated with 2 mg baricitinib, 4 mg bar-
icitinib, and placebo (,1%–2%,15,18 2%–4%,15,18,20,22 and 
2%–3%,15,18 respectively) and similar to those for active 
comparators: MTX – 4%,22 baricitinib plus MTX – 2%,22 
and adalimumab – 2%.20 The IR of serious infections was 
estimated at 2.9 for 100 PYs (95% CI: 2.5; 3.4) for all 
baricitinib-treated patients and 3.8 (95% CI: 2.2; 6.2) for 
individuals receiving 4 mg baricitinib, with no difference 
from placebo (IR =4.2 [95% CI: 2.5; 6.8]), in the integrated 
analysis conducted by Genovese et al26 and Smolen et al.27
Opportunistic infections, such as herpes zoster, were 
not common, but their frequency was slightly higher in 
the 4 mg baricitinib group (2%–4%15,18,20,22) than in the 2 
mg baricitinib group (1%–2%15,18). In most of the reported 
cases, patients previously received bDMARDs15 or were 
of Asian descent.20,22 The integrated analysis of the safety 
profile revealed that the IR of herpes zoster was significantly 
higher after administration of baricitinib at a dose of 4 mg 
(IR =4.3 per 100 PYs) than placebo (IR =1.0 per 100 PYs).26
Major adverse cardiovascular events (MACEs) were rare. 
In the RA-BEACON study, ,1.5% (two cases) of adjudi-
cated MACEs were reported in the 4 mg baricitinib group.15 
A similar ratio was reported in the RA-BEGIN trial:22 ,1% 
of patients treated with baricitinib at a dose of 4 mg and MTX 
experienced MACEs. No cases of MACEs were reported in 
the RA-BUILD study18 in both the 2 and 4 mg baricitinib 
groups. The IR calculated for MACEs was comparable 
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between patients receiving 4 mg baricitinib (IR =0.8 [95% 
CI: 0.2; 2.2] for 100 PYs) and placebo (IR =0.5 [95% CI: 0.1; 
2.0] for 100 PYs).26
Two cases (,1.5%) of cancer (non-melanoma) were 
reported during the administration of baricitinib at a dose of 
4 mg in the RA-BEACON study,15 three cases (,1%) in the 
RA-BEAM study,20 and one case (,1%) in the RA-BUILD18 
and RA-BEGIN study.22 The concomitant use of MTX and 
4 mg baricitinib increased the rate of cancer up to 2%.22 
However, concerning rare AEs, such as malignancies, 
the studies with a relatively short-term follow-up (up to 
52 weeks) may be insufficient to fully analyze this effect. In 
the integrated analysis of RCTs and LTE studies, the IR of 
malignancies (excluding non-melanoma skin cancer) for all 
baricitinib groups (IR =0.8 per 100 PYs) as well as for 4 mg 
baricitinib group (IR =0.5 per 100 PYs) was low and similar 
to that for placebo (IR =0.5 per 100 PYs).26,27
The impact of baricitinib on the reproductive system is 
very poorly understood. Studies in animals have shown terato-
genic effect of baricitinib and decreased female fertility with 
no effect on male spermatogenesis. There are no adequate data 
for the use of baricitinib in pregnant or breast-feeding women 
as well as its influence on fertility, so it is contraindicated dur-
ing pregnancy.13 Only a single case of erectile dysfunction18 
and serious metrorrhagia20 was reported in main clinical trials.
Changes in laboratory parameters
The common effects of baricitinib administration were 
changes in clinical laboratory parameters: neutrophil, lym-
phocyte, and platelet counts as well as hemoglobin, alanine 
aminotransferase, cholesterol, creatinine, and creatine kinase 
levels.15,18,20,22
Inhibition of the JAK/STAT pathway has been associated 
with modifications of hematopoiesis, resulting in changes 
in hematological parameters induced by baricitinib.31 The 
drug was observed to reduce neutrophil count and cause 
a moderate increase in platelet count.15,18,20,22 There were 
no differences between the number of patients experienc-
ing thrombocytosis defined as $600,000 platelets/mm3 in 
groups treated with baricitinib compared with placebo, 
adalimumab, and MTX.15,18,20,22 A transient elevation of the 
lymphocyte count was noted during early administration 
of baricitinib at a dose of 4 mg, but the values returned 
to baseline during weeks 24–52 of treatment.20 A small 
decrease in the hemoglobin level was observed in 2 mg 
and 4 mg baricitinib groups, as compared with placebo;18 
however, the risk of anemia was similar between placebo 
and baricitinib groups.15,18
Baricitinib at a dose of 2 and 4 mg was shown to affect 
liver function seen by a small increase of the alanine amino-
transferase level;15,18,20,22 however, in most cases, the abnor-
malities were transient and generally without concomitant 
bilirubin level elevation.15,18,20
As compared with placebo, the levels of high-density 
lipoprotein (HDL) and low-density lipoprotein (LDL) were 
increased during baricitinib therapy with the 2 mg15,18 and the 
4 mg dose.15,18,20 At 24–52 weeks of 4 mg baricitinib therapy, 
the LDL level stabilized while the HDL level remained 
elevated with a tendency to slowly decrease.20 A higher 
increase of LDL and HDL levels was seen in the baricitinib 
groups than in the MTX monotherapy group.22 However, the 
mechanism of baricitinib’s action on lipoprotein levels was 
not fully understood. It was found that the increase in HDL 
levels was associated with improved clinical outcomes such 
as the Simplified Disease Activity Index and Disease Activity 
Score 28-joint assessment in Phase II trials. Interestingly, no 
similar correlations were observed for the changes in total 
cholesterol, LDL, and triglyceride levels.11
The mean serum creatinine level increased slightly 
during baricitinib treatment15,18,20,22 but did not exceed 
grade 1–2,15,20,22 which means mild-to-moderate severity 
according to Common Terminology Criteria for Adverse 
Events (CTCAE), and was transient in most cases, irrespec-
tive of the length of treatment period.15,18,20,22 The observed 
effect may reflect the small changes in renal function.18
The serum level of creatine kinase increased in the 
4 mg1518,20,22 and the 2 mg baricitinib groups.15,18 The eleva-
tion of creatine kinase levels classified as grade 3 (severe) 
or 4 (life-threatening, according to CTCAE) was rare, and in 
most cases, it resulted from physical activity or abnormalities 
at baseline.15,18,20,22
Baricitinib in the therapy of diseases 
other than RA
The immunosuppressive properties of baricitinib could 
be useful in the treatment of different immune diseases, 
including systemic lupus erythematosus, psoriasis, or atopic 
dermatitis.31–33 The hypothesis that baricitinib might have a 
therapeutic benefit in patients with systemic lupus erythema-
tosus was confirmed in a double-blind, placebo-controlled 
RCT32 conducted in patients with active disease involving the 
skin or joints. The results indicated that baricitinib admin-
istered only as a 4 mg dose significantly improved the signs 
and symptoms of systemic lupus erythematosus in patients 
with inadequate disease control despite standard-of-care 
therapy, with an acceptable safety profile.32 A promising 
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effect of baricitinib on psoriasis was found in an RCT by Papp 
et al.31 Patients with moderate-to-severe psoriasis treated with 
baricitinib achieved significant improvements in the Psoriasis 
Area and Severity Index (PASI)-50 (only at doses of 4, 8, 
or 10 mg) and PASI-75 (only at doses of 8 or 10 mg) over 
placebo. The majority of safety findings were consistent with 
the known safety profile of baricitinib and observed with a 
higher frequency in the groups treated with the 8 and 10 mg 
dose, while the rates of AEs in the 2 and 4 mg dose groups 
were comparable to placebo.31 Another placebo-controlled 
RCT33 revealed that baricitinib at a dose of 4 mg used with 
topical corticosteroids reduced inflammation and pruritus, 
and improved sleep in patients with moderate-to-severe 
atopic dermatitis.
Currently, there are many ongoing Phase II and III 
studies assessing the efficacy and safety of baricitinib in 
populations of patients with lupus erythematosus, atopic 
dermatitis, giant cell arteritis, alopecia areata, and chronic 
graft-vs-host disease (Table 2). The positive results of these 
trials may lead to the extension of registered indications for 
baricitinib in the future.
Conclusion
Baricitinib is a drug with a mechanism of action similar to 
that of tofacitinib but different than that of other products 
approved for the treatment of RA. It may be considered as a 
therapeutic option in some patients with no response to the 
standard therapy. An oral route of administration seems to 
be a quite new and promising alternative, as compared with 
subcutaneous or intravenous biologic drugs. Some RCTs 
revealed a significant benefit of baricitinib over placebo in 
terms of the efficacy outcomes (ACR20, ACR50, and ACR70 
response rates). Clinical trials on baricitinib provided data of 
a good safety profile, with increased incidence of infections 
and abnormal laboratory parameters reported as the most 
common AEs. The majority of AEs proved to be nonseri-
ous and did not lead to treatment discontinuation. Further 
research is needed to provide more information on the clinical 
effectiveness and safety profile of baricitinib.
Disclosure
The authors report no conflicts of interest in this work.
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